Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Short-term Investments (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Short-term Investments data on record, last reported at $230.9 million in Q4 2025.

  • For Q4 2025, Short-term Investments rose 22.55% year-over-year to $230.9 million; the TTM value through Dec 2025 reached $230.9 million, up 22.55%, while the annual FY2025 figure was $230.9 million, 22.55% up from the prior year.
  • Short-term Investments reached $230.9 million in Q4 2025 per TNGX's latest filing, up from $94.5 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $350.0 million in Q1 2022 and bottomed at $428000.0 in Q1 2025.
  • Average Short-term Investments over 5 years is $194.3 million, with a median of $255.3 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: skyrocketed 53047.62% in 2023, then tumbled 99.85% in 2025.
  • A 5-year view of Short-term Investments shows it stood at $342.5 million in 2021, then fell by 10.61% to $306.2 million in 2022, then tumbled by 99.71% to $900000.0 in 2023, then skyrocketed by 20831.89% to $188.4 million in 2024, then grew by 22.55% to $230.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $230.9 million in Q4 2025, $94.5 million in Q3 2025, and $428000.0 in Q2 2025.